Palma DA, et al. - In this randomized, open-label phase 2 study conducted at 10 hospitals in Canada, the Netherlands, Scotland and Australia with 99 patients of 18 years of age and above with a controlled primary tumor and one to five metastatic lesions who satisfied the criteria of Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months. The effect of stereotactic ablative radiotherapy (SABR) on survival, oncological outcomes, toxicity, and quality of life were evaluated in these patients. Results suggest that SABR improved overall survival, which was the primary endpoint of this trial. The researchers suggest a phase 3 trial to deduce an overall survival benefit; 3 out of 66 patients receiving SABR suffered treatment-related death.